Protagonist Therapeutics, Inc.

PTGX

$65.30

Name : Protagonist Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $4,062,399,488.00

EPSttm : 0.73

Protagonist Therapeutics, Inc.

$65.30

0.26%

$0.17

Float Short %

11.34

Margin Of Safety %

-25

Put/Call OI Ratio

0.39

EPS Next Q Diff

-0.06

EPS Last/This Y

-6.45

EPS This/Next Y

1.5

Price

65.27

Target Price

71.71

Analyst Recom

1.21

Performance Q

23.62

Relative Volume

0.7

Beta

2.21

Ticker: PTGX

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-09	PTGX	58.4	0.13	0.01	3362
2025-09-10	PTGX	57.72	0.10	0.00	4227
2025-09-11	PTGX	59.65	0.10	0.28	4287
2025-09-12	PTGX	58.85	0.10	0.00	4318
2025-09-15	PTGX	58.95	0.10	0.04	4611
2025-09-16	PTGX	58.55	0.10	0.02	4483
2025-09-17	PTGX	59.22	0.0928	2.1081081081081	4781
2025-09-18	PTGX	62.15	0.11	0.00	4866
2025-09-19	PTGX	62.22	0.11	0.10	5006
2025-09-22	PTGX	64.54	0.15	0.19	3197
2025-09-23	PTGX	65.06	0.15	0.01	3196
2025-09-24	PTGX	65.98	0.15	0.01	3218
2025-09-25	PTGX	64.69	0.14	0.18	3318
2025-09-26	PTGX	67.39	0.14	0.42	3322
2025-09-29	PTGX	65.11	0.18	0.08	3501
2025-09-30	PTGX	66.45	0.26	0.00	2883
2025-10-01	PTGX	64.19	0.29	0.07	2610
2025-10-02	PTGX	65.02	0.34	0.50	2384
2025-10-03	PTGX	64.82	0.34	0.29	2394
2025-10-06	PTGX	64.12	0.34	1.67	2413
2025-10-07	PTGX	65.44	0.35	2.79	2428
2025-10-08	PTGX	65.28	0.39	0.17	2519
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-09	PTGX	58.39	-14.1	-	-1.98
2025-09-10	PTGX	57.73	-14.1	-	-1.98
2025-09-11	PTGX	59.68	-14.1	-	-1.98
2025-09-12	PTGX	58.83	-14.1	-	-1.98
2025-09-15	PTGX	58.38	-14.1	-	-1.98
2025-09-16	PTGX	58.59	-13.8	-	-1.98
2025-09-17	PTGX	59.23	-13.8	-	-1.98
2025-09-18	PTGX	62.12	-13.8	-	-1.98
2025-09-19	PTGX	62.24	-13.8	-	-1.98
2025-09-22	PTGX	64.51	-13.8	-	-1.98
2025-09-23	PTGX	65.06	-13.8	-	-1.98
2025-09-24	PTGX	65.98	-13.8	-	-1.98
2025-09-25	PTGX	64.70	-13.8	-	-1.98
2025-09-26	PTGX	67.42	-13.8	-	-1.98
2025-09-29	PTGX	65.10	-13.8	-	-1.98
2025-09-30	PTGX	66.43	-13.8	-	-1.98
2025-10-01	PTGX	64.00	-13.8	-	-1.98
2025-10-02	PTGX	64.93	-13.8	-	-1.98
2025-10-03	PTGX	64.82	-13.8	-	-1.98
2025-10-06	PTGX	64.11	-13.7	-	-1.98
2025-10-07	PTGX	65.44	-13.7	-	-1.98
2025-10-08	PTGX	65.27	-13.7	-	-1.98
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-09	PTGX	-4.14	15.15	10.74
2025-09-10	PTGX	-4.14	15.15	10.74
2025-09-11	PTGX	-4.08	15.15	11.66
2025-09-12	PTGX	-4.08	15.15	11.66
2025-09-15	PTGX	-2.59	15.13	11.66
2025-09-16	PTGX	-2.59	15.13	11.66
2025-09-17	PTGX	-2.59	15.13	11.66
2025-09-18	PTGX	-2.59	15.13	11.66
2025-09-19	PTGX	-2.59	15.13	11.66
2025-09-22	PTGX	-2.48	15.11	11.66
2025-09-23	PTGX	-2.48	15.11	11.66
2025-09-24	PTGX	-2.48	15.11	11.66
2025-09-25	PTGX	-2.59	15.11	11.34
2025-09-26	PTGX	-2.59	15.11	11.34
2025-09-29	PTGX	-2.59	15.13	11.34
2025-09-30	PTGX	-2.60	15.13	11.34
2025-10-01	PTGX	-2.60	15.13	11.34
2025-10-02	PTGX	-2.60	15.13	11.34
2025-10-03	PTGX	-2.60	15.13	11.34
2025-10-06	PTGX	-2.60	9.04	11.34
2025-10-07	PTGX	-2.60	9.04	11.34
2025-10-08	PTGX	-2.60	9.04	11.34
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.55

Avg. EPS Est. Current Quarter

-0.61

Avg. EPS Est. Next Quarter

-0.61

Insider Transactions

-2.6

Institutional Transactions

9.04

Beta

2.21

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

48.77

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

4.4

Max Drawdown 5-Year %

-85.8

Target Price

71.71

P/E

91.64

Forward P/E

55338.99

PEG

P/S

19.42

P/B

6.07

P/Free Cash Flow

109.5

EPS

0.71

Average EPS Est. Cur. Y

-1.98

EPS Next Y. (Est.)

-0.48

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

24.88

Relative Volume

0.7

Return on Equity vs Sector %

-17.4

Return on Equity vs Industry %

-3.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Protagonist Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 130

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today

news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance

stock history PTGX – Protagonist Therapeutics Inc invest stock market

stock prices PTGX premarket after hours

ticker PTGX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PTGX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y